摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

trimagnesium;2-hydroxypropane-1,2,3-tricarboxylate

中文名称
——
中文别名
——
英文名称
trimagnesium;2-hydroxypropane-1,2,3-tricarboxylate
英文别名
——
trimagnesium;2-hydroxypropane-1,2,3-tricarboxylate化学式
CAS
——
化学式
C12H10Mg3O14
mdl
——
分子量
451.12
InChiKey
PLSARIKBYIPYPF-UHFFFAOYSA-H
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -11.65
  • 重原子数:
    29
  • 可旋转键数:
    6
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    281
  • 氢给体数:
    2
  • 氢受体数:
    14

ADMET

毒理性
  • 在妊娠和哺乳期间的影响
哺乳期使用的总结:目前没有关于哺乳期间使用柠檬酸镁的临床信息。然而,已经研究了其他镁盐。静脉注射硫酸镁仅略微增加了乳汁中的镁浓度。婴儿对镁的口服吸收不良,因此母体柠檬酸镁不太可能影响哺乳婴儿的血清镁。在怀孕期间补充柠檬酸镁可能会延迟哺乳的开始,但在哺乳期间可以服用,不需要特别的预防措施。 对哺乳婴儿的影响:50位处于分娩后第一天的母亲接受了15毫升的矿物油或矿物油和另一种镁盐的乳液,即相当于900毫克氢氧化镁的氢氧化镁,尽管没有说明具体有多少人接受了每种产品。如果需要,随后的几天可以给予额外的剂量。所有哺乳的婴儿都没有出现明显异常的大便,但所有婴儿也接受了补充喂养。 对哺乳和乳汁的影响:一位因妊娠期高血压接受3天静脉注射硫酸镁的母亲,哺乳II期延迟到分娩后第10天。没有发现延迟的其他具体原因,尽管没有进行完整的评估。随后的对照临床试验发现,接受静脉注射硫酸镁治疗的母亲没有延迟哺乳的证据。一些但不是所有的研究发现,由于镁通过胎盘传递给胎儿,接受分娩期间静脉注射硫酸镁的母亲的孩子在第一次喂养的时间或吸吮能力方面有延长的趋势。 在一项对40对匹配的健康女性进行研究,这些女性经阴道分娩单胎妊娠,比较了那些在分娩前至少4周每天持续口服盐酸天冬氨酸镁补充剂(平均剂量为459毫克,每日范围365至729毫克镁)的妇女与对照组的结局终点。在镁组中,能够在出院时完全用母乳喂养婴儿的妇女明显较少(63%对80%)。
◉ Summary of Use during Lactation:No information is available on the clinical use of magnesium citrate during breastfeeding. However, other magnesium salts have been studied. Intravenous magnesium sulfate increases milk magnesium concentrations only slightly. Oral absorption of magnesium by the infant is poor, so maternal magnesium citrate is not expected to affect the breastfed infant's serum magnesium. Magnesium citrate supplementation during pregnancy might delay the onset of lactation, but it can be taken during breastfeeding and no special precautions are required. ◉ Effects in Breastfed Infants:Fifty mothers who were in the first day postpartum received 15 mL of either mineral oil or an emulsion of mineral oil and another magnesium salt, magnesium hydroxide equivalent to 900 mg of magnesium hydroxide, although the exact number who received each product was not stated. Additional doses were given on subsequent days if needed. None of the breastfed infants were noted to have any markedly abnormal stools, but all of the infants also received supplemental feedings. ◉ Effects on Lactation and Breastmilk:One mother who received intravenous magnesium sulfate for 3 days for pregnancy-induced hypertension had lactogenesis II delayed until day 10 postpartum. No other specific cause was found for the delay, although a complete work-up was not done. A subsequent controlled clinical trial found no evidence of delayed lactation in mothers who received intravenous magnesium sulfate therapy. Some, but not all, studies have found a trend toward increased time to the first feeding or decreased sucking in infants of mothers treated with intravenous magnesium sulfate during labor because of placental transfer of magnesium to the fetus. A study in 40 pairs of matched healthy women with vaginally delivered singleton pregnancies, outcome endpoints were compared in those receiving continuous oral magnesium aspartate HCl supplementation mean dose of 459 mg daily (range 365 to 729 mg of magnesium daily) for at least 4 weeks before delivery versus non-supplemented controls. In the magnesium group, significantly fewer women could breastfeed their infants exclusively at discharge (63% vs 80%).
来源:Drugs and Lactation Database (LactMed)
毒理性
  • 蛋白质结合
镁一旦离子化,就会高度与血浆蛋白结合,它甚至可以代表血液血浆中发现的90%的镁。
Magnesium, once ionized, is highly bound to plasma proteins and it can represent even 90% of the magnesium found in blood plasma.
来源:DrugBank
吸收、分配和排泄
  • 吸收
口服柠檬酸镁后,镁的平均血浆浓度报告为大约0.7毫摩尔/升,唾液中浓度保持在0.28毫摩尔/升。报告还证实,与其他形式(如镁氧化镁)相比,以柠檬酸镁形式给予时,镁的吸收和生物利用度更高。
Mean plasma concentration of magnesium after administration of oral doses of magnesium citrate are reported to be of around 0.7 mmol/L and the concentration in saliva rested in 0.28 mmol/L. In reports, it has also been proven that the absorption and bioavailability of magnesium are greater when administered in the form of magnesium citrate when compared with other forms such as magnesium ocude.
来源:DrugBank
吸收、分配和排泄
  • 消除途径
口服柠檬酸镁后,尿液中的镁排泄量增加了40%。柠檬酸镁也大量通过粪便排出,因为当它存在于肠道中时,它会放松肠道并吸引水分进入肠道,这增加了肠道运动,其中很大一部分药物通过这种方式排出。
After oral administration of magnesium citrate, there is a 40% increase in urine excretion of magnesium. Magnesium citrate is also widely eliminated via the feces because, when present in the bowel, it relaxes the bowel and pulls water into the intestine which increases bowel movement and a significant portion of this agent gets excreted by this via.
来源:DrugBank

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Method for increasing urinary excretion of electrolytes
    摘要:
    本发明公开了一种补充膳食钾、镁和柠檬酸盐的方法,包括口服单一盐酸钾镁柠檬酸盐的有效剂量。本发明还公开了通过口服单一盐酸钾镁柠檬酸盐来降低尿钙和草酸盐的方法。
    公开号:
    US05432200A1
  • 作为产物:
    参考文献:
    名称:
    Bacterial growth medium and method of use
    摘要:
    本文描述了一种改进的粉末细菌培养基组成物,适用于与水混合。粉末培养基包括碱土金属阳离子在化合物A中混合,化合物B包含与化合物A中的碱土金属阳离子反应的阴离子,在水性生长介质中形成基本上不溶于水的盐或碱,包括碱土金属阳离子和阴离子,具有酸中和作用。因此,当化合物A和B被加入水溶液中时,在水性生长介质中形成不溶于水的盐。还描述了一种在水性生长介质中通过形成不溶于水的盐或碱来培养产酸细菌的改进方法。由此产生的生长介质特别适用于中和在各种食品发酵过程中生长的乳酸产生细菌产生的酸。
    公开号:
    US04615978A1
点击查看最新优质反应信息

文献信息

  • Dietary supplementation with potassium magnesium citrate
    申请人:The University of Texas System
    公开号:US05219889A1
    公开(公告)日:1993-06-15
    A method for supplementing dietary potassium, magnesium and citrate is disclosed that comprises orally administering an effective amount of potassium magnesium citrate in a single salt. Methods for decreasing urinary calcium and oxalate by the administration of potassium magnesium citrate in a single salt are also disclosed.
    本发明公开了一种补充膳食钾、镁和柠檬酸盐的方法,该方法包括口服单一盐酸钾镁柠檬酸盐的有效量。本发明还公开了通过口服单一盐酸钾镁柠檬酸盐来降低尿钙和草酸盐的方法。
  • Method for preparation of metal organic acid chelates
    申请人:J H Brotech, Inc.
    公开号:US06670494B1
    公开(公告)日:2003-12-30
    A method is disclosed where organic acid chelates can be made by reacting an organic acid ligand with a metal compound in a non aqueous environment. The chelate is thereafter recovered by means of filtration or evaporation.
    本发明揭示了一种方法,可以在非水环境中通过将有机酸配体与金属化合物反应来制备有机酸螯合物。然后通过过滤或蒸发来回收螯合物。
  • PRODUCTION OF POTASSIUM MAGNESIUM CITRATE AND ITS APPLICATIONS
    申请人:Paikin Michael
    公开号:US20110081456A1
    公开(公告)日:2011-04-07
    Provided is a magnesium rich composition including potassium, magnesium and citrate, a method for producing such a composition and food or nutritional product including the composition.
    提供了一种富含钾、镁和柠檬酸盐的镁质组合物,以及制备该组合物的方法和包括该组合物的食品或营养产品。
  • METHOD FOR TIMING A COLONOSCOPY
    申请人:Joseph Raymond E.
    公开号:US20130018223A1
    公开(公告)日:2013-01-17
    Based on the present disclosure, a minimal time interval can be achieved between the last ingestion of a picosulfate composition and the performance of the colonoscopy. For example, the present disclosure is directed to a method of timing a colonoscopy procedure performed on a patient in need thereof, comprising: administering, to the patient, a picosulfate bowel composition kit according to the kit's instructions; performing the procedure less than about 4 hours after the administration of the kit.
    根据目前的披露,可以在最后一次摄取苦参酚组合物和结肠镜检查之间实现最小时间间隔。例如,本公开涉及一种定时对需要进行结肠镜检查的患者进行结肠镜检查的方法,包括:根据套件的说明向患者施用苦参酚肠道组合物套件;在施用套件后不到约4小时内进行该程序。
  • Production of potassium magnesium citrate and its applications
    申请人:Paikin Michael
    公开号:US08465783B2
    公开(公告)日:2013-06-18
    Provided is a magnesium rich composition including potassium, magnesium and citrate, a method for producing such a composition and food or nutritional product including the composition.
    提供了一种富含钾、镁和柠檬酸盐的镁质组合物,以及制备该组合物的方法和包含该组合物的食品或营养产品。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
ir
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物